SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alembic Pharmaceuticals informs about newspaper publication

16 Sep 2022 Evaluate
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Alembic Pharmaceuticals has informed that it enclosed a copy of the advance notice published in English and vernacular language (Gujarati) newspaper on 16th September, 2022 in Economic Times and Indian Express, English Edition and Financial Express Gujarati Edition, in compliance with Ministry of Corporate Affair's General Circular No. 20/2020 dated 5th May, 2020 inter alia informing the members that the 12th Annual General Meeting of the Company will be held on Friday, the 11th November, 2022 through Video Conferencing ('VC') / Other Audio Visual Means ('OAVM'). 

The above information is a part of company’s filings submitted to BSE.

Alembic Pharma Share Price

785.40 8.05 (1.04%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×